News and features

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

Professor Louis Chesler and Professor Swen Hoelder.
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team

06/03/24

A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the challenge of solid tumours in children.
DNA double helix - computer visualisation
Artificial Intelligence reveals prostate cancer is not just one disease

29/02/24

Artificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer which could revolutionise how the disease is diagnosed and treated in the future.
breast cancer cell
Targeted immunotherapy could lead to pioneering treatment for breast cancer

28/02/24

A new type of immunotherapy that targets non-cancer cells could help prevent the growth and spread of breast cancer tumours, according to new research from the ICR.
A scientist wearing a mask and blue gloves holds a red pill in focus
New drug could unlock benefits of immunotherapy for more patients

27/02/24

A new drug could offer a powerful way to sensitise tumours to immunotherapy, a new trial suggests.
ICR researchers receiving a Queen's Anniversary Prize at Buckingham Palace.
Her Majesty The Queen presents cancer researchers with prize at Buckingham Palace

22/02/24

Earlier today, researchers from The Institute of Cancer Research, London, received a prestigious Queen’s Anniversary Prize on behalf of the institute, in recognition of its transformational breast cancer research programme.
Glioblastoma cells under a microscope
'Olive oil' drug shows early promise for some brain cancer patients

21/02/24

A unique drug derived from oleic acid – which naturally occurs in animal and vegetable fats such as olive oil – has shown promise for patients with an advanced form of the most common type of brain cancer, following a study led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.
Cellular flow model
Researchers develop new approaches to live-track the production of different types of blood cells in mice

19/02/24

Scientists have found a way to monitor in real time how bone marrow stem cells produce the different types of cells in the blood – a process called haematopoiesis.
Graphical abstract from Choudhary paper
New study opens the door to learning more about an important driver of breast cancer

13/02/24

Through innovative exploratory work, scientists have identified a new way to study proteins that are involved in the development of the majority of breast cancers.
Proliferating cells in a tumour organoid of triple-negative breast cancer. Image credit: Dr Rebecca Marlow / ICR
New AI collaboration could advance precision therapy in breast cancer

09/02/24

A new collaboration between academic and industry researchers could help to improve clinical decision making for cancer patients – including by potentially guiding the use of immunotherapy to breast cancer patients who could benefit from it.
ICR Logo
Scientists discover how some advanced breast cancers become resistant to hormone therapy

07/02/24

New research has identified why some advanced oestrogen receptor (ER) positive breast cancers become resistant to hormone therapy, and has identified drugs currently in development that could keep disease stable for longer for these patients.
An artist's impression of The London Cancer Hub
ICR welcomes appointment of Aviva and Socius for new life-sciences development at The London Cancer Hub

22/01/24

The Institute of Cancer Research has welcomed the appointment of a new partnership to deliver a major redevelopment project at The London Cancer Hub in Sutton.
breast cancer cell
ICR welcomes recommendation of talazoparib for advanced breast cancer

19/01/24

The Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer.


Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.